- Home
- BLNK vs ATOS Comparison
BLNK vs ATOS Comparison
Compare BLNK & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- ATOS
- Stock Information
- Founded
- BLNK 2009
- ATOS 2009
- Country
- BLNK United States
- ATOS United States
- Employees
- BLNK N/A
- ATOS N/A
- Industry
- BLNK Industrial Specialties
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- BLNK Consumer Discretionary
- ATOS Health Care
- Exchange
- BLNK Nasdaq
- ATOS Nasdaq
- Market Cap
- BLNK 129.3M
- ATOS 106.9M
- IPO Year
- BLNK N/A
- ATOS 2012
- Fundamental
- Price
- BLNK $1.40
- ATOS $0.80
- Analyst Decision
- BLNK Buy
- ATOS Strong Buy
- Analyst Count
- BLNK 8
- ATOS 3
- Target Price
- BLNK $2.54
- ATOS $6.25
- AVG Volume (30 Days)
- BLNK 2.8M
- ATOS 589.7K
- Earning Date
- BLNK 11-06-2025
- ATOS 11-12-2025
- Dividend Yield
- BLNK N/A
- ATOS N/A
- EPS Growth
- BLNK N/A
- ATOS N/A
- EPS
- BLNK N/A
- ATOS N/A
- Revenue
- BLNK $106,631,000.00
- ATOS N/A
- Revenue This Year
- BLNK N/A
- ATOS N/A
- Revenue Next Year
- BLNK $19.30
- ATOS N/A
- P/E Ratio
- BLNK N/A
- ATOS N/A
- Revenue Growth
- BLNK N/A
- ATOS N/A
- 52 Week Low
- BLNK $0.63
- ATOS $0.55
- 52 Week High
- BLNK $2.65
- ATOS $1.41
- Technical
- Relative Strength Index (RSI)
- BLNK 38.63
- ATOS 36.12
- Support Level
- BLNK $1.35
- ATOS $0.77
- Resistance Level
- BLNK $1.70
- ATOS $0.88
- Average True Range (ATR)
- BLNK 0.13
- ATOS 0.04
- MACD
- BLNK -0.03
- ATOS -0.01
- Stochastic Oscillator
- BLNK 9.79
- ATOS 18.89
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.